Vistagen Therapeutics annual shareholders’ equity
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Vistagen Therapeutics Shareholders’ Equity Growth & History (VTGN)
Vistagen Therapeutics's shareholders’ equity was $35.5M for fiscal 2026.
View full Vistagen Therapeutics company overviewVistagen Therapeutics annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $35.5M | −$34.9M | −49.54% |
| 2025 | 2025-03-31 | $70.4M | −$43.9M | −38.41% |
| 2024 | 2024-03-31 | $114.3M | $102.2M | +846.08% |
| 2023 | 2023-03-31 | $12.1M | −$52.6M | −81.33% |
| 2022 | 2022-03-31 | $64.7M | −$27.3M | −29.64% |
| 2021 | 2021-03-31 | $92.0M | $97.7M | — |
| 2020 | 2020-03-31 | −$5.7M | −$12.8M | — |
| 2019 | 2019-03-31 | $7.1M | $158,600 | +2.29% |
| 2018 | 2018-03-31 | $6.9M | $6.3M | +1023.19% |
| 2017 | 2017-03-31 | $615,800 | $3.6M | — |
| 2016 | 2016-03-31 | −$3.0M | $17.6M | — |
| 2015 | 2015-03-31 | −$20.5M | −$7.7M | — |
| 2014 | 2014-03-31 | −$12.8M | −$243,500 | — |
| 2013 | 2013-03-31 | −$12.6M | −$6.9M | — |
| 2012 | 2012-03-31 | −$5.7M | $27.2M | — |
| 2011 | 2011-03-31 | −$32.9M | −$6.5M | — |
| 2010 | 2010-03-31 | −$26.3M | $346,800 | — |
| 2009 | 2009-03-31 | −$26.7M | −$4.5M | — |
| 2008 | 2008-03-31 | −$22.2M | −$4.7M | — |
| 2007 | 2007-03-31 | −$17.4M | −$945,500 | — |
| 2006 | 2006-03-31 | −$16.5M | −$1.8M | — |
| 2005 | 2005-03-31 | −$14.7M | −$1.1M | — |
| 2004 | 2004-03-31 | −$13.7M | −$8.7M | — |
| 2003 | 2003-03-31 | −$4.9M | −$364,300 | — |
| 2002 | 2002-03-31 | −$4.6M | −$2.1M | — |
| 2001 | 2001-03-31 | −$2.5M | −$1.7M | — |
| 2000 | 2000-03-31 | −$844,100 | −$618,600 | — |
| 1999 | 1999-03-31 | −$225,500 | — | — |
Vistagen Therapeutics quarterly shareholders’ equity
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $24.5M | −$32.3M | −56.87% |
| Q4 2026 | 2026-03-31 | $35.5M | −$34.9M | −49.54% |
| Q3 2026 | 2025-12-31 | $50.9M | −$30.2M | −37.23% |
| Q2 2026 | 2025-09-30 | $66.3M | −$26.6M | −28.65% |
| Q1 2026 | 2025-06-30 | $56.8M | −$48.0M | −45.84% |
| Q4 2025 | 2025-03-31 | $70.4M | −$43.9M | −38.41% |
| Q3 2025 | 2024-12-31 | $81.1M | −$42.2M | −34.20% |
| Q2 2025 | 2024-09-30 | $93.0M | $57.3M | +160.83% |
| Q1 2025 | 2024-06-30 | $104.8M | $98.0M | +1430.19% |
| Q4 2024 | 2024-03-31 | $114.3M | $102.2M | +846.08% |
| Q3 2024 | 2023-12-31 | $123.3M | $102.6M | +496.31% |
| Q2 2024 | 2023-09-30 | $35.6M | $6.0M | +20.40% |
| Q1 2024 | 2023-06-30 | $6.8M | −$39.2M | −85.13% |
| Q4 2023 | 2023-03-31 | $12.1M | −$52.6M | −81.33% |
| Q3 2023 | 2022-12-31 | $20.7M | −$59.3M | −74.15% |
| Q2 2023 | 2022-09-30 | $29.6M | −$51.1M | −63.30% |
| Q1 2023 | 2022-06-30 | $46.1M | −$39.6M | −46.21% |
| Q4 2022 | 2022-03-31 | $64.7M | −$27.3M | −29.64% |
| Q3 2022 | 2021-12-31 | $80.0M | −$13.8M | −14.75% |
| Q2 2022 | 2021-09-30 | $80.7M | $76.4M | +1810.19% |
| Q1 2022 | 2021-06-30 | $85.6M | $91.2M | — |
| Q4 2021 | 2021-03-31 | $92.0M | $97.7M | — |
| Q3 2021 | 2020-12-31 | $93.8M | $99.9M | — |
| Q2 2021 | 2020-09-30 | $4.2M | $7.9M | — |
| Q1 2021 | 2020-06-30 | −$5.6M | −$7.2M | — |
| Q4 2020 | 2020-03-31 | −$5.7M | −$12.8M | — |
| Q3 2020 | 2019-12-31 | −$6.1M | −$7.8M | — |
| Q2 2020 | 2019-09-30 | −$3.6M | −$7.6M | — |
| Q1 2020 | 2019-06-30 | $1.6M | −$1.6M | −49.54% |
| Q4 2019 | 2019-03-31 | $7.1M | $158,600 | +2.29% |
| Q3 2019 | 2018-12-31 | $1.7M | −$8.6M | −83.51% |
| Q2 2019 | 2018-09-30 | $4.0M | $5.7M | — |
| Q1 2019 | 2018-06-30 | $3.2M | $3.8M | — |
| Q4 2018 | 2018-03-31 | $6.9M | $6.3M | +1023.19% |
| Q3 2018 | 2017-12-31 | $10.3M | $7.7M | +296.46% |
| Q2 2018 | 2017-09-30 | −$1.7M | −$5.8M | — |
| Q1 2018 | 2017-06-30 | −$606,800 | −$6.8M | — |
| Q4 2017 | 2017-03-31 | $615,800 | $3.6M | — |
| Q3 2017 | 2016-12-31 | $2.6M | $4.2M | — |
| Q2 2017 | 2016-09-30 | $4.1M | $5.4M | — |
| Q1 2017 | 2016-06-30 | $6.2M | $9.0M | — |
| Q4 2016 | 2016-03-31 | −$3.0M | $17.6M | — |
| Q3 2016 | 2015-12-31 | −$1.6M | $16.2M | — |
| Q2 2016 | 2015-09-30 | −$1.3M | $16.0M | — |
| Q1 2016 | 2015-06-30 | −$2.9M | $12.5M | — |
| Q4 2015 | 2015-03-31 | −$20.5M | −$7.7M | — |
| Q3 2015 | 2014-12-31 | −$17.8M | −$6.1M | — |
| Q2 2015 | 2014-09-30 | −$17.4M | −$4.6M | — |
| Q1 2015 | 2014-06-30 | −$15.4M | −$3.4M | — |
| Q4 2014 | 2014-03-31 | −$12.8M | −$243,500 | — |
| Q3 2014 | 2013-12-31 | −$11.7M | −$1.1M | — |
| Q2 2014 | 2013-09-30 | −$12.8M | −$6.3M | — |
| Q1 2014 | 2013-06-30 | −$11.9M | −$5.7M | — |
| Q4 2013 | 2013-03-31 | −$12.6M | −$6.9M | — |
| Q3 2013 | 2012-12-31 | −$10.5M | −$5.8M | — |
| Q2 2013 | 2012-09-30 | −$6.5M | $2.3M | — |
| Q1 2013 | 2012-06-30 | −$6.3M | $781,156 | — |
| Q4 2012 | 2012-03-31 | −$5.7M | $27.2M | — |
| Q3 2012 | 2011-12-31 | −$4.8M | — | — |
| Q2 2012 | 2011-09-30 | −$8.7M | — | — |
| Q1 2012 | 2011-06-30 | −$7.1M | — | — |
| Q4 2011 | 2011-03-31 | −$32.9M | — | — |
Vistagen Therapeutics shareholders’ equity trends
Over the last five fiscal years, Vistagen Therapeutics's shareholders’ equity decreased from $92.0M to $35.5M, a change of −$56.5M. The latest reported quarter, Q1 2027, shows $24.5M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vistagen Therapeutics source filings ↗